14. SUBSEQUENT EVENT

        In February 2015, we entered into a collaboration agreement with Bristol-Myers Squibb Company (BMS) for the discovery, development and commercialization of cancer immunotherapies based on our extensive portfolio of small molecule TGF beta receptor kinase inhibitors. BMS is required to pay us a noncreditable and nonrefundable upfront payment of $30.0 million. We are also entitled to receive development and regulatory milestones that could total more than $309 million for a successful compound approved in multiple indications. In addition, we are also eligible to receive tiered royalties on the net sales of any products from the collaboration.